Dose-confirmatory Bridging Study in Total Hip Replacement
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The objective of this dose-confirmatory bridging study is to investigate the safety and
efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous
thromboembolism (VTE) in Japanese patients undergoing elective total hip replacement (THR)
and to confirm the extrapolability of global data to Japanese patients by comparing with data
from overseas phase II study (ODIXa-OD.HIP - Study 11527).